drugset / Trial / NCT05803421
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Timeline
- Start
- 2023-04-03
- Primary completion
- 2026-03-16
- Completion
- 2026-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | — | Oral |
| Comparator | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |